Aspire Biopharma Holdings Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
No analyst estimates are published for this company.
Coverage varies across the market: larger companies are often followed by dozens of analysts, while smaller or recently listed ones may have none.
Monitoring Framework
Key Performance Indicators
Net Revenue Quarterly28.4K
Net Loss Quarterly-3.2M
Buzz Bomb Caffeine Supplement Units Manufactured Annually2M
Watch Items
- PCAOB Audit of Dura Driver Control Systems (DCS) for 2024 and 2025Trigger: Unqualified opinion and at least $12 million of gross profit minus capital expendituresAction: Verify compliance before the September 10, 2026 outside date to proceed with or terminate the acquisition.
- FDA 505(b)(2) NDA Submission for High-Dose Sublingual AspirinTrigger: Submission completionAction: Monitor filing progress targeted for late 2026.
- Nasdaq Continued Listing ComplianceTrigger: Minimum bid price and market value requirementsAction: Track stock price stability following the 1-for-30 reverse stock split executed in May 2026.
Research as of 20 Jun 2026